| Autor: |
Arvanitidis, Dimitrios, Anagnostopoulos, George K., Giannopoulos, Dimitrios, Pantes, Athanasios, Agaritsi, Roxanne, Margantinis, George, Tsiakos, Stavros, Sakorafas, George, Kostopoulos, Panagiotis |
| Předmět: |
|
| Zdroj: |
Journal of Gastroenterology & Hepatology; Mar2004, Vol. 19 Issue 3, p278-282, 5p |
| Abstrakt: |
Acute pancreatitis is the most common complication of endoscopic retrogade cholangiopancreatography (ERCP), occurring in 1–10% of patients. Several substances have been used, with negative results, in an attempt to prevent this complication. We performed a double-blind randomized trial in 372 consecutive patients undergoing diagnostic or therapeutic ERCP to evaluate the role of somatostatin in preventing post-ERCP pancreatitis. The first group received continuous somatostatin infusion for 12 h starting 30 min before ERCP, the second group received a bolus intravenous injection of somatostatin at the time of cannulation of the papilla, and the third group received a placebo. Two patients in each of the somatostatin groups (1.7%) and 12 patients in the placebo group (9.8%) developed pancreatitis ( P < 0.05). Serum amylase levels 5 and 24 h after the procedure were lower in both groups that received somatostatin than in the placebo group ( P < 0.05). Somatostatin is useful in preventing post-ERCP pancreatitis. Further studies must be designed to investigate the cost-effectiveness of the drug and to determine the ideal administration route and dosage. © 2004 Blackwell Publishing Asia Pty Ltd [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text